3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Conditions
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Neoplasms
1
Lymphoma, Mantle-Cell
1
Interventions
Rituximab
6
Lenalidomide
3
Bendamustine Hydrochloride
3
pirtobrutinib
2
Cyclophosphamide
2
venetoclax
1
umbralisib
1
ublituximab
1
tocilizumab
1
obinutuzumab
1
idelalisib
1
glofitamab
1
fludarabine
1
atezolizumab
1
acalabrutinib
1
Vincristine
1
Standard of Care
1
Prednisone
1
Doxorubicin
1
Brentuximab Vedotin
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma, Non-Hodgkin
×
Lenalidomide
×
Clear all
NCT05409066
2025-07-28
EPCORE FL-1
Genmab
Phase 3
Active not recruiting
549 enrolled
2 FDA
NCT01996865
2025-07-10
MAGNIFY
Celgene
Phase 3
Completed
503 enrolled
18 charts
1 FDA
NCT01938001
2023-02-22
AUGMENT
Celgene
Phase 3
Completed
358 enrolled
18 charts
1 FDA